Human natural killer cell development and biology

Farag, Sherif; Caligiuri, Michael A.

doi:10.1016/j.blre.2005.10.001

Cited by 436 publications

(368 citation statements)

References 127 publications

Supporting

Mentioning

336

Contrasting

Unclassified

Order By: Relevance

“…2A shows that NK cells, characterized by CD16, NKp30 and NKp46 activator receptors, expressed high levels of PC-PLC on the outer membrane surface. Interestingly, the level of the CD16 antigen was strictly proportional to the amount of externalized PC-PLC in 81.0 AE 7.7% (SD) of NK cells, pointing to a direct correlation between surface PC-PLC expression and NK cell maturation [14,15]. Confocal laser-scanning microscopy (CLSM) analyses on resting, purified NK cells further confirmed flow cytometry results, but showed only limited PC-PLC and CD16 colocalization (Fig.…”

Section: Expression Of Pc-plc On Cd16 + and Cd56 + Nk Subsetssupporting

confidence: 57%

“…It has been reported that CD56 bright CD16 dim NK cells acquire a high level of cytolytic activity and express PFN molecules after IL-2 stimulation [14]. The increased amount of PC-PLC on IL-2-activated CD56 bright cells reinforces the view that a high expression of this active enzyme on the membrane surface parallels the acquisition of an intense lytic activity.…”

Section: Discussionmentioning

confidence: 57%

“…Two distinct NK subpopulations were identified in freshly separated human PBL based on the cell function and relative surface expression of CD16, CD56, inhibitory and chemokine receptors. The majority (about 90%) comprises CD3 -CD56 dim CD16 bright perforin + cytolytic cells, while the minor subset, CD3 -CD56 bright CD16 low/-perforin -, has a greater ability to produce pro-inflammatory cytokines, performing a mostly immunoregulatory function [14]. Recent studies would indicate that immature NK cell precursors express CD16 only at a late stage of differentiation [15,22], although a firm relationship between the CD16 and CD56 levels and NK maturation is still under debate [23,24].…”

Section: Discussionmentioning

confidence: 99%

“…Three-color flow cytometry analyses revealed the existence of two distinct NK cell populations: about 99% of cytolytic CD56 dim CD16 bright cells expressed a massive amount of PC-PLC on the plasma membrane (Fig. 2C, gate e), while CD56 bright CD16 low/-cells, reputed to fulfill a mainly immunoregulatory function [14], expressed low, if any, amounts of PC-PLC on the cell membrane surface (Fig. 2C, gates a, b).…”

Section: Expression Of Pc-plc On Cd16 + and Cd56 + Nk Subsetsmentioning

confidence: 99%

“…Upon activation by IL-2, the cytolytic activity against NK-sensitive targets acquired by CD56 bright cells was similar to, or even greater than that of CD56 dim cells [14,16]. In order to verify whether the acquisition of lytic ability was linked to a higher expression of PC-PLC on the membrane surface, flow cytometry analyses were performed on FACS-purified CD56 bright NK cell subsets.…”

Section: Expression Of Pc-plc On Cd16 + and Cd56 + Nk Subsetsmentioning

confidence: 99%

See 4 more Smart Citations

Expression and role of phosphatidylcholine‐specific phospholipase C in human NK and T lymphocyte subsets

et al. 2006

View full text Add to dashboard Cite

We recently reported evidence of phosphatidylcholine-specific phospholipase C (PC-PLC) involvement in NK cell-mediated cytotoxicity and in lytic granule exocytosis. In the present study, different subpopulations of human PBL were investigated in relation to PC-PLC enzyme expression. While a substantial intracellular amount of PC-PLC was detected in all lymphoid subsets, expression of this enzyme on the outer membrane surface reached high levels only in NK cells, was present at low levels in B lymphocytes and in some TCR gamma/delta T cells and was practically absent in CD4 + and CD8 + T lymphocytes. Moreover, in NK cells two different subpopulations were identified, CD56 dim PC-PLC bright and CD56 bright PC-PLC low/-cells, corresponding to distinct subsets with cytolytic and immunoregulatory functions, respectively. Interestingly, the PC-PLC expression level on the NK membrane surface correlated closely with that of the CD16 receptor, suggesting a possible relationship between enzyme externalization and NK cell maturation. In summary, our results suggest that a high PC-PLC expression on the cell membrane surface of PBL is a peculiarity of NK cytolytic cells, in which the enzyme is apparently involved in the ability of this subset to lyse sensitive target cells.

show abstract

Section: Expression Of Pc-plc On Cd16 + and Cd56 + Nk Subsetssupporting

confidence: 57%

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Section: Expression Of Pc-plc On Cd16 + and Cd56 + Nk Subsetsmentioning

confidence: 99%

Section: Expression Of Pc-plc On Cd16 + and Cd56 + Nk Subsetsmentioning

confidence: 99%

See 3 more Smart Citations

Expression and role of phosphatidylcholine‐specific phospholipase C in human NK and T lymphocyte subsets

et al. 2006

View full text Add to dashboard Cite

show abstract

Nasal and Related Extranodal Natural Killer Cell/T Cell Lymphomas and Blastic Plasmacytoid Dendritic Cell Neoplasm

2016

The Cutaneous Lymphoid Proliferations

View full text Add to dashboard Cite

Cancer Gene Therapy

Tashiro¹,

Scherer²,

Brenner³

2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview The encouraging results of cancer gene therapies have increased their entry into mainstream oncological practice. Gene transfer or gene editing can modify the cellular phenotype and behavior of malignant cells or of host cells, thereby modulating tumor responses. In this article, we discuss both of the above approaches and describe the vector systems that are able to produce the intended genetic modifications. We describe current clinical successes of gene therapy and outline the challenges it has yet to overcome. The success of any gene therapy for cancer requires efficient, safe gene transfer with vectors that can either integrate into the human genome (e.g., retroviral, lentiviral, adeno‐associated viral, or nonviral transposons) or remain largely or completely episomal (e.g., adenoviral, herpesviral, or nonviral plasmids). To date, genetic “correction” of consequential numbers of cancer cells has not proven feasible, but infectious cytolytic viral therapy, used with accompanying immunomodulatory genes within the oncolytic virus, is beginning to demonstrate an impact in the clinic. Enhancement of active cancer immunotherapy with forced expression of antigens and cytokines or the enhancement of adoptive immunotherapy by engineering T lymphocytes with specific T‐cell receptors and/or chimeric antigen receptors shows greatest immediate promise, although ultimately a combination of multiple approaches will prove optimal.

show abstract

Human natural killer cell development and biology

Cited by 436 publications

References 127 publications

Expression and role of phosphatidylcholine‐specific phospholipase C in human NK and T lymphocyte subsets

Expression and role of phosphatidylcholine‐specific phospholipase C in human NK and T lymphocyte subsets

Nasal and Related Extranodal Natural Killer Cell/T Cell Lymphomas and Blastic Plasmacytoid Dendritic Cell Neoplasm

Cancer Gene Therapy

Contact Info

Product

Resources

About